RET protein promotes non-adherent growth of NB-39-nu neuroblastoma cell line

Cancer Science

Volumn 100, Issue 6, 2009, Pages 1034-1039

  Futami, Hitoyasu ^a   Sakai, Ryuichi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; SMALL INTERFERING RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; RET PROTEIN, HUMAN; RNA;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER GROWTH; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN CELL; NERVE CELL GROWTH; NERVE CELL STIMULATION; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; CELL DIVISION; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLIA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NEUROBLASTOMA; NEUROGLIA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RET; RNA INTERFERENCE; RNA, NEOPLASM; RNA, SMALL INTERFERING;

EID: 67649891958     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01143.x     Document Type: Article

References (36)

1. Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 1993, 119:1005-17.
2. Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 1995, 10:191-8.
3. Jain S, Naughton CK, Yang M. Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. Development 2004, 131:5503-13.
4. Donis KH, Dou S, Chi D. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851-6.
5. Mulligan LM, Kwok JB, Healey CS. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363:458-60.
6. Hofstra RM, Landsvater RM, Ceccherini I. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367:375-6.
7. Eng C, Mulligan LM, Smith DP. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 1995, 12:209-12.
8. Eng C, Smith DP, Mulligan LM. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995, 10:509-13.
9. Grieco M, Santoro M, Berlingieri MT. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-63.
10. Bongarzone I, Monzini N, Borrello MG. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RIα of cyclic AMP-dependent protein kinase A. Mol Cell Biol 1993, 13:358-66.
11. Edery P, Lyonnet S, Mulligan LM. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:378-80.
12. Romeo G, Ronchetto P, Luo Y. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:377-8.
13. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-16.
14. Nagao M, Ishizaka Y, Nakagawara A. Expression of ret proto-oncogene in human neuroblastomas. Jpn J Cancer Res 1990, 81:309-12.
15. Ikeda I, Ishizaka Y, Tahira T. Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. Oncogene 1990, 5:1291-6.
16. Borrello MG, Bongarzone I, Pierotti MA. trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages. Int J Cancer 1993, 54:540-5.
17. Hishiki T, Nimura Y, Isogai E. Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFRα-1, and GFRα-2. Cancer Res 1998, 58:2158-65.
18. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-2.
19. Henderson CE, Phillips HS, Pollock RA. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994, 266:1062-4.
20. Arenas E, Trupp M, Akerud P, Ibanez CF. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 1995, 15:1465-73.
21. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005, 16:441-67.
22. Hayashi H, Ichihara M, Iwashita T. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000, 19:4469-75.
23. Ishikawa S, Ohshima Y, Suzuki T, Oboshi S. Primitive neuroectodermal tumor (neuroepithelioma) of spinal nerve root - Report of an adult case and establishment of a cell line. Acta Pathol Jpn 1979, 29:289-301.
24. Kuga N, Yoshida K, Seido T. Heterotransplantation of cultured human cancer cells and human cancer tissues into nude mice. Gann 1975, 66:547-60.
25. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007, 27:7649-60.
26. Drosten M, Stiewe T, Putzer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 2003, 14:971-82.
27. Drosten M, Hilken G, Bockmann M. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 2004, 96:1231-9.
28. Bates RC, Edwards NS, Yates JD. Spheroids and cell survival. Crit Rev Oncol Hematol 2000, 36:61-74.
29. Lawlor ER, Scheel C, Irving J, Sorensen PH. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 2002, 21:307-18.
30. Volk T, Geiger B, Raz A. Motility and adhesive properties of high- and low-metastatic murine neoplastic cells. Cancer Res 1984, 44:811-24.
31. Nabi IR, Raz A. Loss of metastatic responsiveness to cell shape modulation in a newly characterized B16 melanoma adhesive cell variant. Cancer Res 1988, 48:1258-64.
32. Miyake I, Hakomori Y, Misu Y. Domain-specific function of ShcC docking protein in neuroblastoma cells. Oncogene 2005, 24:3206-15.
33. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005, 167:213-22.
34. Hirata Y, Kiuchi K. Mitogenic effect of glial cell line-derived neurotrophic factor is dependent on the activation of p70S6 kinase, but independent of the activation of ERK and up-regulation of Ret in SH-SY5Y cells. Brain Res 2003, 983:1-12.
35. Paratcha G, Ledda F, Ibanez CF. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 2003, 113:867-79.
36. Verity AN, Wyatt TL, Lee W. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. J Neurosci Res 1999, 55:187-97.